Form 4: HealthEquity Executive Sells Shares Under 10b5-1 Plan

HealthEquity Inc. executive Michael Fiore reported a sale of 3,142 shares of common stock, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Fiore, EVP, Chief Commercial Officer at HealthEquity, Inc., reported a transaction on May 29, 2026.
• The transaction involved the sale of 3,142 shares of common stock.
• The sale was conducted under a Rule 10b5-1 trading plan adopted by Mr. Fiore on October 14, 2025.
• Following the transaction, Mr. Fiore beneficially owns 59,113 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it represents a standard stock transaction under a pre-established 10b5-1 plan, which is designed to mitigate insider trading concerns.

Negatives

• Sale of company stock by a key executive.

Risks

• Potential for negative market perception due to executive stock sales, even if conducted under a pre-planned 10b5-1 trading plan.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a stock transaction by an executive.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving Rule 10b5-1 plans, are common for executives to diversify holdings or manage personal finances in a pre-determined manner, aiming to avoid insider trading concerns. However, any executive stock sale can be scrutinized by the market.

Stakeholder Impact

• Shareholders may view executive stock sales, even those under a 10b5-1 plan, with caution, potentially impacting short-term stock sentiment.

Key Dates

Keywords

HealthEquity, HQY, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Executive Compensation, Beneficial Ownership